Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Numerical Abnormalities of Chromosome 9 and p16CDKN2A Gene Deletion Detected by FISH in Non-small Cell Lung Cancer

ANNA D. PANANI, KATERINA MALIAGA, ATHANASIA BABANARAKI and ION BELLENIS
Anticancer Research November 2009, 29 (11) 4483-4487;
ANNA D. PANANI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: apanani{at}med.uoa.gr
KATERINA MALIAGA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATHANASIA BABANARAKI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ION BELLENIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Lung cancer is one of the most common types of cancer worldwide and its pathogenesis is closely associated with various environmental exposures and gene alterations. The identification of genetic changes is a useful strategy toward understanding tumourigenesis and specific genetic associations. Since the tumor suppressor gene p16 located at 9p21 chromosomal region might have an important role in lung carcinogenesis, the aim of the present study was to investigate p16 gene alterations and numerical aberrations of chromosome 9 in non-small cell lung cancer. Materials and Methods: Nineteen cases of non-small cell lung cancer (11 squamous cell carcinomas, 6 adenocarcinomas and 2 large cell carcinomas) were investigated by fluorescence in situ hybridization (FISH) technique using a DNA p16 probe and α-satellite probe specific for chromosome 9. Results: Polysomy 9 was found in 13 cases (6/11 squamous cell carcinomas, 5/6 adenocarcinomas and 2/2 large cell carcinomas). p16 gene alterations were found in 16 cases. Among them, deletion of p16 gene was found in 15 cases (8/11 squamous cell carcinomas, 5/6 adenocarcinomas and 2/2 large cell carcinomas). In six cases with p16 gene deletion, homozygous deletion was observed. Conclusion: Numerical aberrations of chromosome 9 and p16 gene deletion are common findings in all subtypes of non-small cell lung cancer. Despite suggesting the p16 gene in the 9p chromosomal region plays a role in lung carcinogenesis, the presence of other oncogenes reflected by polysomy 9 participating in the neoplastic process cannot be excluded. Data of the present study also suggest, that there might not be a fundamental relationship between genetic changes and histological subtype of non-small cell lung cancer.

  • Lung cancer
  • non-small cell lung cancer
  • genetic changes
  • chromosome 9 numerical abnormalities
  • p16CDKN2A gene deletion
  • FISH technique

Lung cancer is one of the most common types of cancer worldwide and its pathogenesis is closely associated with various environmental exposures and gene alterations. There are poor informative data regarding the sequence of genetic changes leading to lung cancer development. Several reports suggested that a number of molecular genetic and epigenetic events contribute to lung cancer development, while other studies have investigated the use of certain genetic alterations as potential biomarkers in early detection or risk assessment of lung cancer (1-9).

The tumor suppressor gene p16CDKN2A seems to have an important role in lung carcinogenesis. It is located at 9p21 and encodes a cell cycle protein that is an inhibitor of cyclin dependent kinases (CDK) 4 and 6 and negatively regulates cyclin D-dependent phosphorylation of the Rb gene product, thus blocking cell cycle progression from the G1- to the S-phase. Loss of function of p16 gene has been reported to occur mainly by homozygous deletions, mutations or aberrant DNA methylation of the promoter region (1, 10-13).

The aim of the present study was to investigate both numerical aberrations of chromosome 9 and p16 gene alterations in surgically resected tumors of non-small cell lung cancer (NSCLC) by fluorescence in situ hybridization (FISH) technique.

Materials and Methods

Reviewing cancerous tumors cytogenetically studied in our laboratory, 51 patients with NSCLC were found who had undergone surgical resection of the tumors between the years 2004 and 2005. Since the p16 gene is considered to play an important role in lung carcinogenesis, among methods used for cytogenetic evaluation of the cases studied, FISH technique using a DNA p16 probe had been performed in 19 lung cancer cases. These cases were included in the present study. Eleven cases had squamous cell carcinoma of low differentiation, six cases had adenocarcinomas, while two cases were large cell carcinomas. Tissue specimens were collected from fresh surgically resected tumors. None of the patients had ever received chemotherapy or radiation prior to surgery. Further clinical data regarding tumor biological behavior or disease outcome were not available for the cases studied. A small portion of each resected tumor was directly processed for cytogenetic study as described elsewhere (14). FISH technique was applied to recently made slides from methanol/acetic acid-fixed cells using a DNA p16 probe and α-satellite probe specific for chromosome 9. The p16 probe (Cytocell Ltd, Cambridge UK), labeled red, covered a 101 kb region of 9p21, extending from 59 kb 3′ of p16 to the 5′ end of p15. The probe mix also contained a control probe for chromosome 9 (D9Z3, the hetechromatic block at 9q12), labeled green. FISH was carried out according to the manufacturer's instructions. The hybridization of the probe with the cellular DNA site was visualized by fluorescence microscopy using a NIKON E600 equipped with selective filters for the fluorochromes used. Cells with deletion of p16 gene have either one red signal and two green controls if the deletion is hemizygous, or no red but two green signals if the deletion is homozygous. A minimum of 200 non-overlapping cells from each slide were evaluated for each case. Signals were scored using the criteria of Hopman et al. (15). To avoid misinterpretation due to technical error, normal lymphocyte nuclei were used as a control. Approximately 96% of control lymphocyte nuclei showed two red signals for p16 gene and two green signals for the 9q12 chromosomal region. A case was counted as aberrant if more than 10% of the cell nuclei showed losses or gains of signals for chromosome 9 or p16 gene. This study was approved by the local Ethical Committee.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Numerical aberrations of chromosome 9 and p16 gene alterations in 19 cases of non-small cell lung cancer.

Results

Results are shown in Table I. Numerical aberrations of chromosome 9 were found in 13 out of 19 cases studied (Figure 1); polysomy 9 was found in all 13 cases. Among them, 6 cases had squamous cell carcinomas, 5 cases adenocarcinomas and 2 cases large cell carcinomas. In 2 cases (cases 4 and 5) there were two cell populations, one with polysomy 9 and the other with monosomy 9. p16 gene alterations were found in 16 cases. Among them, deletion of p16 gene (red spots<green spots) was found in 15 cases (8 cases of squamous cell carcinomas, 5 cases of adenocarcinomas and 2 cases of large cell carcinomas). In one case of squamous cell carcinoma (case 4), 36.44% of the examined cells exhibited one red and one green spot. In addition, in this case, 57.36% of the examined cells presented gains of p16 gene equal to chromosome 9 copies. In six cases with p16 gene deletion, homozygous deletion was observed in 62.38, 65.04, 24.56, 41.67, 51.40 and 21.00% of the examined cells, respectively.

Discussion

Several studies have investigated the genetic alterations in lung carcinogenesis in order to predict prognosis and develop new therapeutic strategies, but no specific molecular marker has as yet been defined in lung cancer. Molecular studies focusing on the tumor suppressor gene p16 showed that p16 inactivation has an important role in lung carcinogenesis. It was reported that p16 gene is inactivated in up to 70% of NSCLC tumor specimens but rarely in small cell lung cancer (SCLC).The inactivation of p16 is mainly caused by homozygous deletions, mutations or promoter hypermethylation of the gene. The rate of mutation of p16 is relatively low in NSCLC, whereas homozygous deletions of the gene can be found in 10-40% of the tumors. It has also been reported that aberrant methylation of p16 gene is an early event in lung cancer (1, 10, 16-20). Most of the studies regarding p16 gene alterations were based on polymerase chain reaction (PCR) analysis techniques or immunohistochemistry for gene protein expression (11, 16-17, 20).

We utilized FISH to study numerical aberrations of chromosome 9 and p16 gene alterations in NSCLC. The FISH technique is considered the most reliable method for detecting homozygous gene deletions. Numerical abnormalities of chromosome 9 were found in 13 cases whereas deletion of p16 gene was observed in 15 cases. In one case (case 4) with cells exhibiting both monosomy and polysomy of chromosome 9, 36.44% of the examined cells exhibited one red and one green spot; moreover, 57.36% of the examined cells presented gains of p16 gene equal to chromosome 9 copies. It seems evident, that in cases with 1 red and 1 green spot, loss of p16 gene is due to chromosome 9 monosomy. Similarly, in cases with gains of p16 gene copies equal to those of chromosome 9, the gains of p16 gene copies result from chromosome 9 polysomy.

Dessy et al. (17) studied chromosome 9 and p16 gene alterations by FISH technique and immunohistochemistry in the tumor specimens of 31 patients with squamous cell carcinomas and in 31 adjacent normal bronchi specimens. They found numerical aberrations of chromosome 9 in 19/31 patients, whereas p16 gene alterations were present in 29/31 cases. In that study, among cases with p16 gene alterations, 8 cases with polysomy of chromosome 9 also had gains of copies of p16 gene. However, it was not clear in the above cases, whether the p16 gene copies were equal to or fewer than the copies of chromosome 9. Moreover, 4 patients with monosomy of chromosome 9 had one copy of p16 gene. The authors also concluded that inactivation of p16 gene is an early event in the evolution of the bronchial epithelium towards carcinoma.

Regarding histological type, numerical aberrations of chromosome 9 were observed in 6/11 squamous cell carcinomas, 5/6 adenocarcinomas and in 2/2 large cell carcinomas. Deletion of p16 gene was observed in 8/11 squamous cell carcinomas, in 5/6 adenocarcinomas and in 2/2 large cell carcinomas. Although, the number of cases studied was too small in order to detect any relationship between histopathological types of lung cancer and genetic changes by statistical analysis, it seems that numerical aberrations of chromosome 9 and p16 gene deletion are shared by all histological subtypes of NSCLC.

Several studies have described common chromosomal abnormalities in lung cancer, but little is known about the mechanisms behind these chromosomal changes (21-23). Although chromosomal changes in lung carcinomas may be recurrent, they lack diagnostic specificity; they are considered part of a stepwise process facilitating the identification of genes important in carcinogenesis. Regarding chromosome 9 aberrations, besides the p16 gene in the 9p chromosomal region, the presence of other oncogenes in concert with polysomy of chromosome 9 participating in the neoplastic process cannot be excluded.

Interestingly, in one study, all published cases of cytogenetically aberrant lung cancers in the Mitelman Database of Chromosome Aberrations in Cancer, 432 cases in total, were statistically analyzed to detect possible karyotypic pathways and possible cytogenetic subtypes (23). It was found that the profiles for adenocarcinomas, squamous and large cell carcinomas were very similar. On the other hand, p16 gene alterations were described in several types of malignant diseases, including hematological malignancies (24). Regarding lung cancer, several studies have shown that p16 inactivation occurred in all histological subtypes of NSCLC (16-17). Data of the present study also suggested that there might not be a fundamental relationship between genetic changes and any particular histological subtype of NSCLC. Therefore, the fact that similar recurrent genetic abnormalities have been observed within different histological subtypes of NSCLC, might suggest that there are no fundamental tissue-specific differences in the genetic changes by which lung neoplasia is initiated or progresses. However, in order to establish the above concept more cytogenetic information is needed.

In conclusion, FISH technique using the cocktail probes of α-satellite probe specific for chromosome 9 and a specific probe for p16 gene is a valuable method for simultaneously detecting numerical abnormalities of chromosome 9 and p16 gene deletion. Numerical aberrations of chromosome 9 and p16 gene deletion are common findings in all subtypes of NSCLC, suggesting that there might not be a fundamental relationship between genetic changes and the histological subtype of NSCLC. Besides the p16 gene on 9p chromosomal region being suggested as playing a role in lung carcinogenesis, the presence of other oncogenes in association with polysomy of chromosome 9 participating in the neoplastic process cannot be excluded. Genetic changes leading to lung cancer development or progression are of major importance and need to be thoroughly investigated, thus also contributing to the classification of this disease.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Copy number of chromosome 9 (green spots) and p16 gene (red spots) detected by FISH in lung cancer cells from different cases.

  • Received June 30, 2009.
  • Revision received September 29, 2009.
  • Accepted October 6, 2009.
  • Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Panani AD,
    2. Roussos C
    : Cytogenetic and molecular aspects of lung cancer. Cancer Lett 239: 1-9, 2006.
    OpenUrlCrossRefPubMed
    1. Huber RM
    . And Stratakis DF: Molecular oncology-perspectives in lung cancer. Lung Cancer 45: S209-S213, 2004.
    OpenUrlCrossRefPubMed
    1. Cheng S,
    2. Gao Y,
    3. Dong X,
    4. Lu Y,
    5. An Q,
    6. Tong T,
    7. Wang Y
    : Molecular and cytogenetic alterations in early stage of carcinogenesis of human lung. Cancer Lett 162: S5-S10, 2001.
    OpenUrlPubMed
    1. Wistuba I,
    2. Behrens C,
    3. Milchgrub S,
    4. Bryant D,
    5. Hung J,
    6. Minna JD,
    7. Gazdar AF
    : Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18: 643-650, 1999.
    OpenUrlCrossRefPubMed
    1. Mao L
    : Molecular abnormalities in lung carcinogenesis and their potential clinical implications. Lung Cancer 34: 527-534, 2001.
    OpenUrl
    1. Kettunen E,
    2. Anttila S,
    3. Seppanen JK,
    4. Karjalainen A,
    5. Edgren H,
    6. Lindstrom I,
    7. Salovaara R,
    8. Nissen A-M,
    9. Salo J,
    10. Mattson K,
    11. Hollmen J,
    12. Knuutila S,
    13. Wikman H
    : Differentially expressed genes in non-small cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 149: 98-106, 2004.
    OpenUrlCrossRefPubMed
    1. Steels E,
    2. Paesmans M,
    3. Berghmans T,
    4. Branle F,
    5. Lemaitre F,
    6. Mascaux C,
    7. Meert AP,
    8. Vallot F,
    9. Lafitte JJ,
    10. Sculier JP
    : Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705-719, 2001.
    OpenUrlAbstract/FREE Full Text
    1. Huncharek M,
    2. Kuplnick B,
    3. Geschwind JF,
    4. Caubet JF
    : Prognostic significance of P53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett 153: 219-226, 2000.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Yakut T,
    2. Egeli U,
    3. Gebitekin C
    : Investigation of C-MYC and P53 gene alterations in the tumor and surgical borderline tissues of NSCLC and effects on clinicopathologic behavior: By the FISH technique. Lung 181: 245-258, 2003.
    OpenUrlPubMed
  3. ↵
    1. Belinsky SA,
    2. Nikula KJ,
    3. Palmisano WA,
    4. Michels R,
    5. Saccomanno G,
    6. Gabrielson E,
    7. Baylin SB,
    8. Herman JG
    : Aberrant methylation of P16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891-11896, 1998.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Mariatos G,
    2. Gorgoulis VG,
    3. Zacharatos P,
    4. Kotsinas A,
    5. Vogiatzi T,
    6. Rassidakis G,
    7. Foukas P,
    8. Liloglou T,
    9. Tiniakos D,
    10. Angelou N,
    11. Manolis EN,
    12. Veslemes M,
    13. Field JK,
    14. Kittas C
    : Expression of p16INK4A and alterations of the 9p21-23 chromosome region in non-small cell lung cancer carcinomas: relationship with tumor growth parameters and ploidy status. Int J Cancer 89: 133-141, 2000.
    OpenUrlCrossRefPubMed
    1. Geradts J,
    2. Fong KM,
    3. Zimmerman PV,
    4. Maynard R,
    5. Minna JD
    : Correlation of abnormal RB, P16INK4a and P53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 5: 791-800, 1999.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Liggett WH,
    2. Sidransky D
    : Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197-1206, 1998.
    OpenUrlAbstract
  6. ↵
    1. Stamouli M,
    2. Ferti AD,
    3. Panani AD,
    4. Raftakis J,
    5. Consoli C,
    6. Raptis SA,
    7. Young BD
    : Application of multiplex fluorescence in situ hybridization in the cytogenetic analysis of primary gastric carcinoma. Cancer Genet Cytogenet 135: 23-27, 2002.
    OpenUrlPubMed
  7. ↵
    1. Hopman AHN,
    2. Ramaekers FCS,
    3. Raap AK,
    4. Beck JLM,
    5. Deville P,
    6. Ploeg M,
    7. Vooijs GP
    : In situ hybridization as a tool to study numerical aberrations in solid bladder tumors. Histochemistry 89: 307-316, 1988.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Tanaka R,
    2. Wang D,
    3. Morishita Y,
    4. Inadome Y,
    5. Minami Y,
    6. Iijima T,
    7. Fucai S,
    8. Goya T,
    9. Noguchi M
    : Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer 103: 608-615, 2005.
    OpenUrlPubMed
  9. ↵
    1. Dessy E,
    2. Rossi E,
    3. Berenzi A,
    4. Tironi A,
    5. Benetti A,
    6. Grigolato P
    : Chromosome 9 instability and alterations of p16 gene in squamous cell carcinoma of the lung and in adjacent normal bronchi: FISH and immunohistochemical study. Histopathology 52: 475-482, 2008.
    OpenUrlCrossRefPubMed
    1. Kraunz KS,
    2. Nelson HH,
    3. Lemos M,
    4. Goldleski JJ,
    5. Wiencke JK,
    6. Kesley KT
    : Homozygous deletion of p16INK4a and tobacco carcinogen exposure in non-small cell lung cancer. Int J Cancer 118: 1364-1369, 2006.
    OpenUrlCrossRefPubMed
    1. Nakata S,
    2. Sugio K,
    3. Uramoto H,
    4. Oyama T,
    5. Hanagiri T,
    6. Morita M,
    7. Yasumoto K
    : The methylation status and protein expression of CDH1, p16INK4A and fragile histidine triad in non-small cell lung canrcinoma. Cancer 106: 2190-2199, 2006.
    OpenUrlPubMed
  10. ↵
    1. Jin M,
    2. Inoue S,
    3. Umemura T,
    4. Moriya J,
    5. Arakawa M,
    6. Nagashima K,
    7. Kato H
    : Cyclin D1, P16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 34: 207-218, 2001.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Balsara BR,
    2. Testa JR
    : Chromosomal imbalances in human lung cancer. Oncogene 21: 6877-6883, 2002.
    OpenUrlCrossRefPubMed
    1. Pei J,
    2. Balsara BR,
    3. Li W,
    4. Litwin S,
    5. Gabrielson E,
    6. Feder M,
    7. Jen J,
    8. Testa JR
    : Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosome Cancer 31: 282-287, 2001.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Hoglund M,
    2. Gisselsson D,
    3. Hansen GB,
    4. Mitelman F
    : Statistical dissection of cytogenetic patterns in lung cancer reveals multiple modes of karyotypic evolution independent of histological classification. Cancer Genet Cytogenet 154: 99-109, 2004.
    OpenUrlPubMed
  13. ↵
    1. Tsirigotis P,
    2. Pappa V,
    3. Labropoulos S,
    4. Papageorgiou S,
    5. Kontsioti F,
    6. Dervenoulas J,
    7. Papageorgiou E,
    8. Panani A,
    9. Mantzios G,
    10. Economopoulos T,
    11. Raptis S
    : Mutation and methylation analysis of cyclin-dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia. Eur J Haematol 76: 230-236, 2006.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 29, Issue 11
November 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Numerical Abnormalities of Chromosome 9 and p16CDKN2A Gene Deletion Detected by FISH in Non-small Cell Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Numerical Abnormalities of Chromosome 9 and p16CDKN2A Gene Deletion Detected by FISH in Non-small Cell Lung Cancer
ANNA D. PANANI, KATERINA MALIAGA, ATHANASIA BABANARAKI, ION BELLENIS
Anticancer Research Nov 2009, 29 (11) 4483-4487;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Numerical Abnormalities of Chromosome 9 and p16CDKN2A Gene Deletion Detected by FISH in Non-small Cell Lung Cancer
ANNA D. PANANI, KATERINA MALIAGA, ATHANASIA BABANARAKI, ION BELLENIS
Anticancer Research Nov 2009, 29 (11) 4483-4487;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Significance of Chr9p22.1-p21.3 Deletion in Cancer Development: A Pan-cancer In Silico Analysis
  • Detection of Numerical Abnormalities of Chromosome 9 and p16/CDKN2A Gene Alterations in Ovarian Cancer with Fish Analysis
  • Google Scholar

More in this TOC Section

  • IBP1 Represses the Migration and Invasion of Hepatocellular Carcinoma Cells by Inhibiting SOCE-dependent Formation of Neutrophil Extracellular Traps by Targeting the Akt Pathway
  • Proinsulin Promotes Tumor Development in the PANC-1 Pancreatic Adenocarcinoma Cell Line
  • Metformin Induces PARP1-mediated Cell Death in NPC/HK1 Human Nasopharyngeal Carcinoma Cells
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire